OncoMatch/Clinical Trials/NCT06534437
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Is NCT06534437 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including MEN1703 and Glofitamab for non-hodgkin lymphoma, b-cell.
Treatment: MEN1703 · Glofitamab — The goal of the study is to assess the safety and anti-lymphoma activity of MEN1703 (Dapolsertib hydrochloride) when given as a single-agent or combined with glofitamab to patients with relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma. The study will be open to groups at the same time: * Group 1 - patients who have not had anti-CD3xCD20 bispecific antibody therapy but who have had at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma * Group 2 - patients who have exhausted all standard treatment options including at least 2 prior lines of systemic treatment for aggressive B-cell non-Hodgkin lymphoma Group 1 patients will be treated for a maximum of 12 cycles. One cycle is 21 days. Group 2 with be treated until the disease progresses, therefore treatment duration is dependent on the number of treatment cycles a participant receives prior to progression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic treatment
Relapsed or refractory disease having received at least 2 prior lines of systemic treatment
Cannot have received: PIM inhibitor
Prior treatment with a PIM inhibitor
Lab requirements
Blood counts
Adequate hematologic function
Kidney function
Adequate organ function at Screening
Liver function
Adequate organ function at Screening
Cardiac function
No myocardial infarction within 6 months, NYHA Class III or IV heart failure, uncontrolled dysrhythmias, or poorly controlled angina; QTc <480 ms (up to 500 ms if mild prolongation is well controlled)
Adequate organ function at Screening; Adequate hematologic function; Cardiac dysfunction is defined as myocardial infarction within 6 months of study entry, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, or poorly controlled angina. History of serious ventricular arrhythmia (e.g., VT or VF, ≥3 beats in a row), or QT interval corrected for heart rate (QTc) ≥480 ms. Note: QTc values up to 500 ms will be acceptable where patient's medical history e.g., bundle branch block, is known to cause mild QTc prolongation and the condition is well controlled.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify